The Spallation Neutron Source — already the world’s most powerful accelerator-based neutron source — will be on a planned hiatus through June 2024 as crews work to upgrade the facility. Much of the work — part of the facility’s Proton Power Upgrade project — will involve building a connector between the accelerator and the planned Second Target Station.
ORNL has launched a new entrepreneurial start-up program, Safari, as an addition to DOE's Office of Technology Transitions Practices to Accelerate the Commercialization of Technologies program. Safari seeks to connect post-exit entrepreneurs with commercially relevant technologies developed by world-leading scientific experts, which could provide the basis for a new business.
Speakers, scientific workshops, speed networking, a student poster showcase and more energized the Annual User Meeting of the Department of Energy’s Center for Nanophase Materials Sciences, or CNMS, Aug. 7-10, near Market Square in downtown Knoxville, Tennessee.
The Department of Energy’s Office of Science has selected three ORNL research teams to receive funding through DOE’s new Biopreparedness Research Virtual Environment initiative.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
A new nanoscience study led by a researcher at ORNL takes a big-picture look at how scientists study materials at the smallest scales.
A licensing agreement between the Department of Energy’s Oak Ridge National Laboratory and research partner ZEISS will enable industrial X-ray computed tomography, or CT, to perform rapid evaluations of 3D-printed components using ORNL’s machine
Technologies developed by researchers at ORNL have received six 2023 R&D 100 Awards.
A group at the Department of Energy's Oak Ridge National Laboratory made a difference for local youth through hands-on projects that connected neutron science and engineering intuitively.
After a highly lauded research campaign that successfully redesigned a hepatitis C drug into one of the leading drug treatments for COVID-19, scientists at ORNL are now turning their drug design approach toward cancer.